Scinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

All right. I think we're live now. So let's jump in. Thank you, everyone, for joining today. SINAi Immunotherapeutics corporate overview and 2026 mid year business update. My name is Andrew Erickson. I'm a managing director here at Allel Capital who works directly with the SINAI team and we're helping put on this event today. I'm going to run through a bit of the first half results that you might have noticed SINAI published just yesterday. I'll review some of those financials, some of those business updates, and then Amir is going to give us a bit of an outlook for the rest of 2026 and why the team is ultimately really excited about what's to come. Without further ado, we'll get into it and then we'll save the questions at the end. If you're watching on LinkedIn or YouTube, there's chat boxes for both of those platforms. Submit your questions and we'll get to those at the end of the conversation. Without further ado, let's jump into the call here, Amir, maybe what you can do is I'm sure a lot of people on the call are familiar with who you are, but maybe just a quick background on yourself and your role at SINAI and then we can get into some of the first half details. Thank you very much, Andrew, and welcome everybody to our webinar today. I'm Amir Reitman. I have a biotechnology engineering master's degree and an MBA from the Wharton School of Penn University. My background goes back more than twenty years in pharmaceutical industry between The United States, Europe and Israel. And now I'm leading SINAI as the CEO of SINAI Immunotherapeutics, the parent company and also of the subsidiary, Sinai Biopharma Services, our CDMO doctor company. With that, let's kind of jump in. As we discussed, the first half results got published yesterday. Think there was a lot of posi...